Cargando…

NOTCH1 Signalling: A key pathway for the development of high-risk chronic lymphocytic leukaemia

NOTCH1 is a cell surface receptor that releases its intracellular domain as transcription factor upon activation. With the advent of next-generation sequencing, the NOTCH1 gene was found recurrently mutated in chronic lymphocytic leukaemia (CLL). Here, virtually all NOTCH1 mutations affect the prote...

Descripción completa

Detalles Bibliográficos
Autor principal: Edelmann, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606825/
https://www.ncbi.nlm.nih.gov/pubmed/36313682
http://dx.doi.org/10.3389/fonc.2022.1019730
_version_ 1784818386112348160
author Edelmann, Jennifer
author_facet Edelmann, Jennifer
author_sort Edelmann, Jennifer
collection PubMed
description NOTCH1 is a cell surface receptor that releases its intracellular domain as transcription factor upon activation. With the advent of next-generation sequencing, the NOTCH1 gene was found recurrently mutated in chronic lymphocytic leukaemia (CLL). Here, virtually all NOTCH1 mutations affect the protein’s PEST-domain and impair inactivation and degradation of the released transcription factor, thus increasing NOTCH1 signalling strength. Besides sequence alterations directly affecting the NOTCH1 gene, multiple other genomic and non-genomic alterations have by now been identified in CLL cells that could promote an abnormally strong NOTCH1 signalling strength. This renders NOTCH1 one of the key signalling pathways in CLL pathophysiology. The frequency of genomic alterations affecting NOTCH1 signalling is rising over the CLL disease course culminating in the observation that besides TP53 loss, 8q gain and CDKN2A/B loss, NOTCH1 mutation is a hallmark genomic alteration associated with transformation of CLL into an aggressive lymphoma (Richter transformation). Both findings associate de-regulated NOTCH1 signalling with the development of high-risk CLL. This narrative review provides data on the role of NOTCH1 mutation for CLL development and progression, discusses the impact of NOTCH1 mutation on treatment response, gives insight into potential modes of NOTCH1 pathway activation and regulation, summarises alterations that have been discussed to contribute to a de-regulation of NOTCH1 signalling in CLL cells and provides a perspective on how to assess NOTCH1 signalling in CLL samples.
format Online
Article
Text
id pubmed-9606825
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96068252022-10-28 NOTCH1 Signalling: A key pathway for the development of high-risk chronic lymphocytic leukaemia Edelmann, Jennifer Front Oncol Oncology NOTCH1 is a cell surface receptor that releases its intracellular domain as transcription factor upon activation. With the advent of next-generation sequencing, the NOTCH1 gene was found recurrently mutated in chronic lymphocytic leukaemia (CLL). Here, virtually all NOTCH1 mutations affect the protein’s PEST-domain and impair inactivation and degradation of the released transcription factor, thus increasing NOTCH1 signalling strength. Besides sequence alterations directly affecting the NOTCH1 gene, multiple other genomic and non-genomic alterations have by now been identified in CLL cells that could promote an abnormally strong NOTCH1 signalling strength. This renders NOTCH1 one of the key signalling pathways in CLL pathophysiology. The frequency of genomic alterations affecting NOTCH1 signalling is rising over the CLL disease course culminating in the observation that besides TP53 loss, 8q gain and CDKN2A/B loss, NOTCH1 mutation is a hallmark genomic alteration associated with transformation of CLL into an aggressive lymphoma (Richter transformation). Both findings associate de-regulated NOTCH1 signalling with the development of high-risk CLL. This narrative review provides data on the role of NOTCH1 mutation for CLL development and progression, discusses the impact of NOTCH1 mutation on treatment response, gives insight into potential modes of NOTCH1 pathway activation and regulation, summarises alterations that have been discussed to contribute to a de-regulation of NOTCH1 signalling in CLL cells and provides a perspective on how to assess NOTCH1 signalling in CLL samples. Frontiers Media S.A. 2022-10-13 /pmc/articles/PMC9606825/ /pubmed/36313682 http://dx.doi.org/10.3389/fonc.2022.1019730 Text en Copyright © 2022 Edelmann https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Edelmann, Jennifer
NOTCH1 Signalling: A key pathway for the development of high-risk chronic lymphocytic leukaemia
title NOTCH1 Signalling: A key pathway for the development of high-risk chronic lymphocytic leukaemia
title_full NOTCH1 Signalling: A key pathway for the development of high-risk chronic lymphocytic leukaemia
title_fullStr NOTCH1 Signalling: A key pathway for the development of high-risk chronic lymphocytic leukaemia
title_full_unstemmed NOTCH1 Signalling: A key pathway for the development of high-risk chronic lymphocytic leukaemia
title_short NOTCH1 Signalling: A key pathway for the development of high-risk chronic lymphocytic leukaemia
title_sort notch1 signalling: a key pathway for the development of high-risk chronic lymphocytic leukaemia
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606825/
https://www.ncbi.nlm.nih.gov/pubmed/36313682
http://dx.doi.org/10.3389/fonc.2022.1019730
work_keys_str_mv AT edelmannjennifer notch1signallingakeypathwayforthedevelopmentofhighriskchroniclymphocyticleukaemia